A5018858121- Lymphoma Diagnosis and Treatment
- Chronic Lymphocytic Leukemia Research
- CNS Lymphoma Diagnosis and Treatment
- Immunodeficiency and Autoimmune Disorders
- Viral-associated cancers and disorders
- Cardiac tumors and thrombi
- CAR-T cell therapy research
- Bone health and treatments
- Acute Myeloid Leukemia Research
- Medical Imaging Techniques and Applications
- Lung Cancer Treatments and Mutations
- Multiple Myeloma Research and Treatments
- Cutaneous lymphoproliferative disorders research
- Cell death mechanisms and regulation
- Acute Lymphoblastic Leukemia research
- Gastrointestinal Tumor Research and Treatment
- Radiomics and Machine Learning in Medical Imaging
- Hematopoietic Stem Cell Transplantation
- Histiocytic Disorders and Treatments
- Peptidase Inhibition and Analysis
- Parvovirus B19 Infection Studies
- Immunotherapy and Immune Responses
- Myeloproliferative Neoplasms: Diagnosis and Treatment
- Sarcoma Diagnosis and Treatment
- Galectins and Cancer Biology
401 General Military Hospital of Athens
2014-2022
Athens Medical Center
2013-2019
Piedmont Athens Regional
2014-2015
National and Kapodistrian University of Athens
2011
Abstract Transplant‐ineligible relapsed/refractory (rr) diffuse large B‐cell lymphoma (DLBCL) patients represent an unmet medical need. Polatuzumab vedotin (Pola), anti‐CD79b antibody‐drug‐conjugate (ADG), with bendamustine‐ rituximab(BR) has recently gained approval for these patients, both in the USA and Europe, based on GO29365 phase IIb trial. Real‐life data Pola are extremely limited. We report outcomes of 61 Greek who received Pola‐(B)R mainly within a compassionate use program....
The optimal treatment approach for patients with mantle cell lymphoma (MCL) is not well defined. Intensive therapeutic regimens result in high response rates and prolonged progression-free survival but at the expense of significant toxicity. We report here our results administration rituximab plus chlorambucil (R-Chl) as first line MCL. Twenty consecutively diagnosed were treated this combination which an induction a maintenance arm included. During induction, was administered dose 375 mg/m2...
Abstract Background R-CHOP can cure approximately 75% of patients with primary mediastinal large B-cell lymphoma (PMLBCL), but prognostic factors have not been sufficiently evaluated yet. R-da- EPOCH is potentially more effective also toxic than R-CHOP. Reliable classification needed to guide treatment decisions. Materials and Methods We analyzed the impact clinical on outcome 332 PMLBCL ≤65 years treated ± radiotherapy in a multicenter setting Greece Cyprus. Results With median follow-up 69...
Low absolute lymphocyte count (ALC) to monocyte (AMC) ratio (ALC/AMC) is an independent prognostic factor in Hodgkin lymphoma (HL), but different cutoffs (1.1, 1.5, and 2.9) have been applied. We aimed validate the significance of ALC/AMC 537 homogenously treated (doxorubicin, bleomycin, vinblastine, dacarbazine or equivalents ± radiotherapy) classical HL patients at various cutoffs. The median was 2.24 (0.44-20.50). AMC 0.653 × 10(9)/L (0.050-2.070). Lower associated with established...
A number of studies have looked into the pathophysiological role angiogenesis in CLL, but results often been inconsistent. We aimed to gain direct insight angiogenic process lymph nodes involved by focusing on proangiogenic cytokines and microvessel morphometry. The tissue levels VEGF, Th-2 IL-6 IL-8, IL-8 receptor CXCR2, tyrosine p-STAT-3/SOCS-3 axis modulating cytokine expression were evaluated immunohistochemically 62 CLL/SLL cases. Microvascular characteristics image analysis. Results...
Aim: To examine the real-life impact of baseline positron-emission tomography/computed tomography (PET/CT) in Hodgkin lymphoma (HL). Patients and Methods: A total 162 consecutive patients with HL were retrospectively studied. Results: Disease was up-staged 26 (16%) down-staged 9 (6%). However, treatment strategy modified only 10 (6% total). Involved field radiotherapy delineated according to PET/CT 36/66 (59%). These modifications did not significantly affect outcome. Moreover, three potent...
Abstract Clonal B‐cell lymphocytosis of marginal zone origin (CBL‐MZ) is a recently described entity characterized by the presence clonal B cells in blood and/or bone marrow (BM) with morphologic and immunophenotypic features consistent derivation otherwise healthy individuals. CBL‐MZ commonly associated paraproteinemia, usually immunoglobulin M (IgM), raising diagnostic difficulties from Waldenstrom macroglobulinemia (WM). The aim present study was to determine MYD‐88 L265P mutation...
We have analyzed the immunohistochemical expression of a wide range molecules along with proliferation rate separately in centers (PCs) and rest tumor area, lymph node or spleen sections patients chronic lymphocytic leukemia (CLL). Fas, FasL c-FLIP were observed both within outside PCs all cases. However, only difference between non-PC areas attained statistical significance. Median survivin was higher compared to areas. Cleaved caspase 3 expressed at very low levels PCs, while BCL-2 protein...
The established treatment algorithms for chronic lymphocytic leukemia (CLL)/small lymphoma (SLL) are currently challenged by novel classes of drugs, with ibrutinib being one the most effective. Published data suggest that patients early progression under often emerge as having Richter's transformation (RT) a rapidly fatal prognosis, mostly developing diffuse large B-cell (DLBCL). In this respect, it is known RT to DLBCL occurs in about 5% CLL during disease course and less frequently Hodgkin...
Primary mediastinal large B-cell lymphoma (PMLBCL) is an aggressive non-Hodgkin (NHL), whose prognosis has greatly improved since the incorporation of anti-CD20 monoclonal antibody rituximab into current therapeutic regimens. Evidence, however, on optimal time interval between consecutive chemoimmunotherapy (CIT) cycles still scarce. This study aimed to evaluate efficacy outcomes more commonly administered 3-weekly regimens biweekly ones in a PMLBCL patients' population, who were mostly...
Only few studies have focused exclusively on patients with small lymphocytic lymphoma (SLL).In the present report, 103 SLL were analyzed from both, clinical trials of German Chronic Lymphocytic Leukemia Study Group and Greek centers, emphasis was placed therapeutic strategy. The impact lymph node characteristics, such as presence proliferation centers (PCs) response survival also assessed.SLL included in treated mostly fludarabine-based regimens while those "real-life" staged low-grade...
Data concerning angiogenesis in chronic lymphocytic leukaemia (CLL) indicate that CLL patients are characterized by various abnormalities the angiogenic profile including increased microvessel density lymph nodes and bone marrow levels of certain pro-angiogenic vascular growth factors. Vascular endothelial factor (VEGF) its receptors, basic fibrobast (bFGF) matrix metalloproteinases(MMPs) were found to be highly expressed while there was no difference angiogenin expression between healthy...
As the interaction between hematopoietic stem cells (HSCs) and endosteal endothelial niches in HSCs homing is essential, we aimed to study bone turnover angiogenesis 29 patients with lymphoma/multiple myeloma undergoing cell transplantation (HSCT).Serum samples were collected before high-dose chemotherapy (HDT), at end of HDT, after HSC infusion, nadir myelotoxicity, engraftment. Bone metabolism (CTX, TRACP-5b, bALP, OC, DKK1, RANKL, OPG), (Ang1, Ang2) markers measured. These also measured...
CASE REPORT A 67-year-old female, nonsmoker, was admitted to the pulmonary department of our hospital because chronic cough that had started 3 months earlier and abnormal chest radiography. Her medical history significant for rheumatoid arthritis been in remission without any treatment about 2 years. Two years previously she diagnosed with acute myeloid leukemia not otherwise specified, M7 type (megakaryoblastic). She received induction chemotherapy a complete response achieved. Thereafter,...
Composite lymphomas (CLs) are characterized by the rare occurrence of two or more morphologically and/or immunophenotypically different in same anatomic tissue site. Many combinations lymphoma have been reported including multiple B-cell lymphomas, and T-cell non Hodgkin complex B-cell, cases. The components usually not clonally related but use thorough molecular techniques revealed that some cases suggesting origin from a common progenitor cell. Pathogenesis these remains well defined...